Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

NCT07187908 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

1076

Enrollment

OTHER_GOV

Sponsor class

Conditions

Primary/Secondary Prevention
High Risk for Febrile Neutropenia of Chemotherapy Regimens
Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia

Interventions

DRUG: Efbemalenograstim alfa Injection

Sponsor

Henan Cancer Hospital

Collaborators

[object Object]